Table 4

The relationship between supratherapeutic voriconazole drug levels during therapy and adverse drug events
Variable Voriconazole level ≤ 5.5 mg/L (n = 92) Voriconazole level > 5.5 mg/L (n = 16) OR [95% CI]
Any adverse drug event* 36 (39.1%) 9 (56.3%) 2.00 [0.60-6.89]
Adverse drug event by subtype*
Encephalopathy 15 (16.3%) 6 (37.5%) 3.08 [0.79-11.0]
LFT abnormalities (AST/ALT > 5x ULN, Alk phos/bili >3x ULN) 11 (12.0%) 4 (25.0%) 2.45 [0.49-10.1]
Acute renal failure (creatinine rise ≥ 0.3 mg/L in 48 hours)§ 4 (4.3%) 4 (25.0%) 7.33 [1.17-43.8]
Visual changes 5 (5.4%) 0 (0%) --
Drug rash 6 (6.5%) 1 (6.3%) 0.96 [0.02-8.81]

*For at least one month after initiation of therapy.

†Fisher’s exact test.

§Baseline creatinine 1.1 in 4 subjects with therapeutic levels, and 1.3 in 4 subjects with supratherapeutic levels, all with eventual acute renal failure.

Chu et al.

Chu et al. BMC Infectious Diseases 2013 13:105   doi:10.1186/1471-2334-13-105

Open Data